M
MindRank AI
MindRank AI is a developer of proprietary end-to-end AI-driven drug-discovery platform (Molecule Pro™)
About MindRank AI
MindRank AI is a pioneering startup that operates at the intersection of artificial intelligence (AI), biology, and chemistry to revolutionize drug discovery. The company's primary focus is to expedite the process of drug discovery by leveraging machine learning and AI technologies. Their clientele primarily consists of biopharma companies, with whom they collaborate to develop AI-enabled drug discovery solutions, particularly for hard-to-drug molecular targets.
Read full description
MindRank's business model is centered around the development of proprietary drugs and the provision of AI-enabled drug discovery services. Their proprietary drug, MDR-001, a GLP-1 RA designed to treat obesity and type 2 diabetes mellitus, received US IND approval in just 19 months. The company also successfully delivered an allosteric inhibitor with Best-in-Class potential to a publicly traded biotech company.
The company generates revenue through the sale of its proprietary drugs and the provision of AI-enabled drug discovery services to biopharma companies. MindRank's team of over 40 scientists, including top biopharma experts and global AI competition winners, brings a wealth of industry experience and success in drug discovery and AI-driven technological innovations.
MindRank has been recognized for its innovative work, being named one of Forbes Asia's "100 to Watch" in 2023. It has also secured funding from the Dynamic Resilience program and had its proprietary AI solution nominated as one of the "Top AI Breakthroughs in Biopharma from 2018 to 2020" by Deep Pharma Intelligence.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Hangzhou, China
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 78.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Biotech and Pharma, AI Drug Discovery, Techbio
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2026 | $52M | $208M | RMB Funds | ↗ |
| SERIES A✓Equity / VC | Jul 2023 | $20M | $80M | Guangzhou Xie Nuo Investment Group | ↗ |
Growth signals
Latest recorded traffic for MindRank AI is 4.4K monthly website visits, up 193.3% over the last three months. MindRank AI's team grew 17.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Sherpa Venture Partners
Green Pine Capital
Huagai Capital
Guangzhou Xie Nuo Investment Group
RMB Funds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MindRank AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MindRank AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.